Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 10 July 2019, 12:27 HKT/SGT
Share:
    

Source: Eisai
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry

TOKYO, July 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.

G2D2 integrates Eisai's strengths cultivated from human genetics, data sciences and precision chemistry for the novel drug discovery approach, and this approach will focus on the immunodementia to expand Eisai's dementia pipeline beyond amyloid-beta (A beta) and tau. Specifically, G2D2 will leverage human genetics and human biology to attempt to discover potential innovative medicines for dementia, which target the brain?s immune system.

G2D2 is located in Cambridge, Massachusetts, one of the world?s leading biotechnology clusters where academic institutions and private research organizations are concentrated, and will collaborate with the world-class science. Taking advantage of the benefits of its location, The Eisai Incubator for
NeuroDiscovery (e-IND) will provide space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics. G2D2 also plans to contribute to the development of next-generation scientific leaders in the Boston and Cambridge areas through internships, training programs and postdoctoral fellowships in genetics and drug discovery science.

With the full-scale operation of G2D2, Eisai is striving to discover innovative dementia treatments using a multi-dimensional, comprehensive approaches to fulfill unmet needs and increase the benefits for patients and their families.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Media Inquiries
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


July 10, 2019 12:27 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Multimedia
(Standing from left to right) Ryan Fattman, U.S. Senator for Massachusetts; Mike Belleville, patient living with dementia; Haruo Naito, Eisai CEO; Yoshito Kishi, Morris Loeb Professor of Chemistry, Harvard University; Yasushi Nakamura, Acting Consul General at Consulate General of Japan in Boston; Mark Fuller, Undersecretary for Business Growth, Executive Office of Economic Development.
View Image
 

Eisai
July 11, 2019 12:59 HKT/SGT
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11, 2019 09:04 HKT/SGT
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 8, 2019 09:31 HKT/SGT
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
June 18, 2019 12:32 HKT/SGT
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18, 2019 12:11 HKT/SGT
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
May 29, 2019 09:05 HKT/SGT
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 17, 2019 15:34 HKT/SGT
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 16, 2019 07:37 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 10, 2019 12:34 HKT/SGT
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10, 2019 11:55 HKT/SGT
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: